Analysts Offer Insights on Healthcare Companies: PAVmed Inc (NASDAQ: PAVM) and Aurinia Pharmaceuticals (NASDAQ: AUPH)

By Carrie Williams

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PAVmed Inc (PAVMResearch Report) and Aurinia Pharmaceuticals (AUPHResearch Report) with bullish sentiments.

PAVmed Inc (PAVM)

In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on PAVmed Inc, with a price target of $3. The company’s shares closed yesterday at $1.03.

Vendetti noted:

“Business update call on May 21, 2019, was positive. The initial first-in-human (FIH) CarpX patients were treated successfully without adverse events. the company announced it successfully treated nine patients, of the approximate 20 it expects to treat, in its FIH clinical study, which will be used for its 510(k) re-submission. EsoCheck has completed its largest hurdle, receiving an FDA opinion that it met the substantial equivalent of its predicate. PAVmed reported 1Q19 results and filed its 10-Q on with opex slightly below our estimate and GAAP EPS inline with our expectation.”

According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 2.9% and a 46.9% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Restoration Robotics Inc, Xtant Medical Holdings, and Ra Medical Systems Inc.

PAVmed Inc has an analyst consensus of Moderate Buy, with a price target consensus of $3.

See today’s analyst top recommended stocks >>

Aurinia Pharmaceuticals (AUPH)

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Aurinia Pharmaceuticals, with a price target of $25. The company’s shares closed yesterday at $6.49.

According to TipRanks.com, Arce is a 4-star analyst with an average return of 8.7% and a 39.0% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Arcturus Therapeutics Ltd, and Melinta Therapeutics Inc.

Currently, the analyst consensus on Aurinia Pharmaceuticals is a Strong Buy with an average price target of $17.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.